Compound Evidence File
#EC-2026-0861
Isotretinoin
Filed under Oral Tablets. The bureau holds 78 laboratory returns for this compound from 26 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
26 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 6 | 10.0 | 9.9 | 10.0 | 23 May 2026 | 23 May 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 5 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 4 | 10.0 | 10.0 | 10.0 | 18 Nov 2025 | 11 Jul 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 10.0 | 9.9 | 10.0 | 21 Dec 2025 | 27 May 2026 |
| BachemCASE #VI-2026-0314 | A | 2 | 10.0 | 10.0 | 10.0 | 7 Apr 2026 | 14 Jun 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 4 | 9.9 | 9.9 | 9.9 | 14 Nov 2025 | 11 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 9.9 | 9.9 | 10.0 | 10 Feb 2026 | 22 May 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 4 | 9.9 | 9.9 | 10.0 | 16 Apr 2026 | 22 Jul 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 3 | 9.9 | 9.9 | 10.0 | 15 Dec 2025 | 5 Jul 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 3 | 9.9 | 9.9 | 10.0 | 27 Mar 2026 | 13 Jul 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 10.0 | 20 Feb 2026 | 8 Apr 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 2 | 9.9 | 9.9 | 10.0 | 16 May 2026 | 7 Jul 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 2 | 9.9 | 9.9 | 10.0 | 18 Feb 2026 | 3 Jul 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 2 | 9.9 | 9.9 | 10.0 | 4 Jun 2026 | 13 Jul 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 2 | 9.9 | 9.9 | 10.0 | 15 Apr 2026 | 2 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 7 | 8.7 | 7.1 | 10.0 | 24 May 2026 | 24 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 4 | 8.7 | 7.7 | 9.9 | 24 May 2026 | 24 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 4 | 8.3 | 7.5 | 9.6 | 25 May 2026 | 25 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 7 | 8.2 | 6.5 | 9.5 | 21 May 2026 | 21 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 2 | 7.7 | 6.8 | 8.5 | 21 May 2026 | 21 May 2026 |
| Simple PeptideCASE #VI-2026-0782 | X | 1 | 7.5 | 7.5 | 7.5 | 13 Jun 2025 | 13 Jun 2025 |
| Astro PeptidesCASE #VI-2026-0424 | X | 1 | 6.2 | 6.2 | 6.2 | 27 Feb 2025 | 27 Feb 2025 |
| Quenna PMQCASE #VI-2026-0415 | X | 1 | 5.0 | 5.0 | 5.0 | 13 Feb 2025 | 13 Feb 2025 |
| Peptides 4 ResearchCASE #VI-2026-0511 | X | 1 | 4.4 | 4.4 | 4.4 | 13 Jun 2025 | 13 Jun 2025 |
| Zhuoyue BiotechnologyCASE #VI-2026-0632 | X | 1 | 3.4 | 3.4 | 3.4 | 7 May 2025 | 7 May 2025 |
| Lejian Biotech PeptideCASE #VI-2026-0746 | X | 1 | 0.0 | 0.0 | 0.0 | 3 Jul 2025 | 3 Jul 2025 |
Open any subject to view the batch-level evidence for Isotretinoin alone.